Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PARP14 | Q460N5 | 5/20 | 0.56 |
| ▸ | PARP1 | P09874 | 11/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867230 | 0.88 | CYP1A2 (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5337975 | 0.88 | CYP1A2 (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL222876 | 0.86 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29435026 | 0.86 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL8268111 | 0.86 | HDAC3 (0.53) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4514014 | 0.86 | HDAC3 (0.53) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29029431 | 0.85 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL22018723 | 0.85 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15789054 | 0.85 | RAB9A (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7439456 | 0.85 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2025264818-A1 | STAT6 MODULATORS AND METHODS OF USES THEREOF | RAYTHERA, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | disclosed |
| CN-1158281-C | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | ��һ��������ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
| CN-1239478-A | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LTD (JP) | 1999-12-22 | — | — | CN | disclosed |
| EP-0958297-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999007704-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | HDAC3 883/4885HDAC1 249/4885HDAC2 536/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | HDAC3 883/4885HDAC1 249/4885HDAC2 536/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | HDAC3 883/4885HDAC1 249/4885HDAC2 536/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | HDAC3 883/4885HDAC1 249/4885HDAC2 536/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | HDAC3 883/4885HDAC1 249/4885HDAC2 536/4885 |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | HDAC3 138/4885HDAC1 77/4885HDAC2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.